Guest: Suresh S. Ramalingam, MD

In this discussion, Dr. Ramalingam will assess the value offered by checkpoint inhibitors in the treatment of NSCLC, alone and in combination with chemotherapy and how to incorporate the mutational load and PD-L1 expression as biomarkers when selecting a therapeutic approach for your patients. Dr. Ramalingam will also cover the wide range of checkpoint inhibitor targets/immunotherapies and their potential combination with non-immune treatment modalities. Dr. Suresh Ramalingam is an internationally recognized lung cancer physician-investigator. Dr. Ramalingam has authored over 200 scientific publications and is the section editor for "Chest Diseases" for the journal, Cancer. He is also on the editorial boards of the Journal of Clinical Oncology, Annals of Oncology, and Clinical Lung Cancer.